Diasorin
DiaSorin S.p.A., headquartered in Italy, is a prominent player in the global diagnostics industry, specialising in the development and production of innovative diagnostic solutions. Founded in 1968, the company has established a strong presence in major operational regions, including Europe, North America, and Asia. With a focus on immunodiagnostics and molecular diagnostics, DiaSorin offers a range of unique products, including its LIAISON® and Simplexa™ platforms, which are renowned for their accuracy and efficiency. The company has achieved significant milestones, such as expanding its product portfolio and enhancing its technological capabilities, solidifying its market position as a leader in the field. Recognised for its commitment to quality and innovation, DiaSorin continues to advance healthcare diagnostics, making a meaningful impact on patient care worldwide.
DitchCarbon Score
How does Diasorin's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Other Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Diasorin's score of 48 is higher than 94% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Diasorin's reported carbon emissions
In 2023, Diasorin reported total carbon emissions of approximately 15,001,000 kg CO2e, comprising 3,894,000 kg CO2e from Scope 1 and 15,000,000 kg CO2e from Scope 2 emissions. The company has set a significant climate commitment, aiming for Net Zero emissions by 2050, with this target encompassing all scopes of emissions. This long-term goal reflects Diasorin's dedication to sustainability and reducing its carbon footprint across its global operations. Comparatively, in 2022, Diasorin's emissions were about 15,264,000 kg CO2e, indicating a slight reduction in total emissions year-on-year. The company has been actively disclosing its emissions data, focusing on transparency and accountability in its climate initiatives. In the UK, Diasorin's emissions for 2023 were reported at 374,000 kg CO2e, with 85,000 kg CO2e from Scope 1, 18,000 kg CO2e from Scope 2, and 272,000 kg CO2e from Scope 3 emissions. This data highlights the company's efforts to monitor and manage its carbon emissions effectively. Overall, Diasorin's commitment to achieving Net Zero by 2050 positions it as a proactive player in the healthcare industry, addressing climate change and striving for a sustainable future.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2014 | 2015 | 2016 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 617,530 | 000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 9,489,510 | 0,000,000 | 0,000,000 | 00,000,000 | 00,000,000 | 0,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Diasorin is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
